Economic Evaluation of Entresto for the Treatment of Heart Failure With Reduced Ejection Fraction in Adult Patients With Nyha Class Ii or Iii in Canada

Model parameters influencing the cost-effectiveness of sacubitril/valsartan in heart failure: evidence from a systematic literature review

“…A total of 22 full-text publications, 15 conference abstracts, and 5 HTA reports (1 each from the NICE [ 17 ], US ICER [ 61 ], CADTH [ 58 ], PBAC [ 60 ] and SMC [ 59 ]) were included. Of these, seven were from the US [ 18 , 20 , 30 , 33 , 35 , 52 , 61 ], three from Canada [ 51 , 55 , 58 ], three from Australia [ 27 , 56 , 60 ], and two each from the UK [ 17 , 41 ], Germany [ 32 , 48 ], Italy [ 29 , 50 ], the Netherlands [ 21 , 43 ], Russia [ 53 , 57 ], and Singapore [ 19 , 40 ]. Seventeen of the included studies were published by academic research institutions.…”

“…Another model from the US assumed that patients had a monthly risk of HF hospitalization, non-HF hospitalization, emergency department (ED) visit for HF, treatment intolerance, and cardiovascular or non-cardiovascular death [ 20 ]. Several models were also based on HF patients transitioning between the four New York Heart Association (NYHA) functional classes (I–IV) and death [ 19 , 35 , 49 , 51 , 52 ]. A simpler structure based on two health states, “alive” and “dead”, was also commonly used across models.…”

“…A total of 22 full-text publications, 15 conference abstracts, and 5 HTA reports (1 each from the NICE [17], US ICER [61], CADTH [58], PBAC [60] and SMC [59]) were included. Of these, seven were from the US [18,20,30,33,35,52,61], three from Canada [51,55,58], three from Australia [27,56,60], and two each from the UK [17,41], Germany [32,48], Italy [29,50], the Netherlands [21,43], Russia [53,57], and Singapore [19,40] From additional bibliography (n = 1) chronic HFrEF in the outpatient setting, three studies modeled patients stabilized in hospital after an acute decompensation for HF [33,56,57] (Supplementary Table S4).…”

“…The mean age of patients in these models ranged from 60 [35,36] to 75 years [43], with the majority of patients being male [25,28,29,41,43,45]. Among models that reported information on the NYHA functional class [19,20,25,28,29,32,35,42,43,[50][51][52], the majority of patients were in NYHA class II. Most models used enalapril as the comparator, cost-utility analysis as the economic analysis type, payer's perspective, lifetime horizon, and a monthly cycle.…”